AZN.ST - AstraZeneca PLC

Stockholm - Stockholm Real Time Price. Currency in SEK
661.70
+2.10 (+0.32%)
At close: 5:29PM CEST
Stock chart is not supported by your current browser
Previous Close659.60
Open659.90
Bid661.20 x 0
Ask661.40 x 0
Day's Range656.30 - 663.70
52 Week Range519.10 - 722.70
Volume175,145
Avg. Volume289,277
Market Cap818.774B
Beta0.82
PE Ratio (TTM)313.60
EPS (TTM)2.11
Earnings DateN/A
Forward Dividend & Yield23.28 (3.44%)
Ex-Dividend Date2018-08-09
1y Target Est91.01
  • Reuters10 hours ago

    AstraZeneca CEO warns of medicine shortages after Brexit: Sunday Times

    Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times. The company said in July it would stockpile drugs as a Brexit safety net, and CEO Pascal Soriot told the Sunday Times in an interview that the complexity of the supply chain in pharmaceuticals meant that delays would be likely. Separately, the Sunday Times reported that Jaguar Land Rover was considering following BMW's lead and bringing forward its annual summer factory shutdown to coincide with Britain's departure from the EU in case there is no deal, but added no decision had been taken.

  • Reuters16 hours ago

    AstraZeneca ceo warns of medicine shortages after Brexit - Sunday Times

    Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times. The company said in July it would stockpile drugs as a Brexit safety net, and CEO Pascal Soriot told the Sunday Times in an interview that the complexity of the supply chain in pharmaceuticals meant that delays would be likely. Separately, the Sunday Times reported that Jaguar Land Rover was considering following BMW's lead and bringing forward its annual summer factory shutdown to coincide with Britain's departure from the EU in case there is no deal, but added no decision had been taken.

  • 3 High-Yield Stocks at Rock-Bottom Prices
    Motley Foolyesterday

    3 High-Yield Stocks at Rock-Bottom Prices

    Looking for big yield at a discount? These three could fit the bill.

  • NVS vs. AZN: Which Stock Is the Better Value Option?
    Zacks2 days ago

    NVS vs. AZN: Which Stock Is the Better Value Option?

    NVS vs. AZN: Which Stock Is the Better Value Option?

  • Reuters4 days ago

    FOCUS-AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON, Sept 19 (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters. Surrounded by the latest gizmos at the World Internet of Things Exposition in Wuxi, eastern China, Soriot says he wants to use the power of artificial intelligence, robots and apps to help transform diagnosis and disease management.

  • AstraZeneca's Fasenra Long-Term Asthma Study Data Positive
    Zacks4 days ago

    AstraZeneca's Fasenra Long-Term Asthma Study Data Positive

    AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.

  • Reuters4 days ago

    Focus: AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China. Tech tie-ups with the likes of Alibaba and Tencent will not directly lift the British group's drug sales, since they are not specific for any one company's products and in many cases will be low-cost or free. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters.

  • AstraZeneca plots China robot offensive to counter price cuts
    Reuters4 days ago

    AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca (AZN.L) aims to move from simply supplying drugs to become a broad healthcare provider in China. Tech tie-ups with the likes of Alibaba (BABA.N) and Tencent will not directly lift the British group's drug sales, since they are not specific for any one company's products and in many cases will be low-cost or free. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters.

  • AstraZeneca-Backed ADC Therapeutics Weighs IPO, Sale
    Bloomberg6 days ago

    AstraZeneca-Backed ADC Therapeutics Weighs IPO, Sale

    ADC Therapeutics SA, a Swiss biotechnology company whose backers include U.K. drugmaker AstraZeneca Plc, is in the early stages of exploring options including an initial public offering amid growing interest in innovative cancer treatments, according to people familiar with the matter. ADC is working with advisers at Morgan Stanley on a preliminary review, the people said, asking not to be identified because the deliberations are private. The Lausanne-based company -- which specializes in treatments that target cancer cells while sparing healthy ones -- is also considering a potential sale among the options, they said.

  • Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
    Zacks9 days ago

    Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

    Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

  • AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia
    Zacks9 days ago

    AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia

    AstraZeneca's (AZN) rare blood cancer candidate receives approval from the FDA for relapsed or refractory hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies.

  • Reuters10 days ago

    FDA approves AstraZeneca's drug for rare form of blood cancer

    The U.S. Food and Drug Administration said on Thursday it approved AstraZeneca Plc's treatment for hairy cell leukemia, a slow-growing type of blood cancer. The treatment, marketed as Lumoxiti, was approved for treating a stubborn form of the disease or a relapse in patients who have received at least two prior therapies, the FDA https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620448.htm said. Lumoxiti includes a boxed warning advising health care professionals and patients about the risk of developing capillary leak syndrome, a condition in which fluid and proteins leak out of tiny blood vessels.

  • Motley Fool10 days ago

    3 Lung Cancer Stocks That Could End September on a High Note

    This year's World Conference on Lung Cancer has some important presentations scheduled.

  • The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
    Zacks13 days ago

    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

  • Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
    Zacks16 days ago

    Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus

    Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.

  • AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status
    Zacks16 days ago

    AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status

    AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.

  • Benzinga16 days ago

    The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Sept. 6) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR )(announced positive ...

  • Does AstraZeneca PLC’s (LON:AZN) Debt Level Pose A Problem?
    Simply Wall St.16 days ago

    Does AstraZeneca PLC’s (LON:AZN) Debt Level Pose A Problem?

    Investors pursuing a solid, dependable stock investment can often be led to AstraZeneca PLC (LON:AZN), a large-cap worth UK£72.22b. Doing business globally, large caps tend to have diversified revenue streamsRead More...

  • AstraZeneca gets FDA breakthrough therapy label for asthma treatment
    Reuters16 days ago

    AstraZeneca gets FDA breakthrough therapy label for asthma treatment

    The drug, tezepelumab, is an injectable treatment that is expected to help a wider range of patients than existing asthma medicines like GlaxoSmithKline's Nucala. A breakthrough therapy status is designed to expedite the development and regulatory review of medicines that are intended to treat a serious condition and that have shown encouraging early clinical results.

  • Reuters16 days ago

    AstraZeneca gets FDA breakthrough therapy label for asthma treatment

    AstraZeneca Plc and Amgen Inc said on Friday the U.S. Food and Drug Administration had granted a breakthrough therapy label for their drug to treat a type of severe asthma, potentially speeding up its development and regulatory review. The drug, tezepelumab, is an injectable treatment that is expected to help a wider range of patients than existing asthma medicines like GlaxoSmithKline's Nucala. A breakthrough therapy status is designed to expedite the development and regulatory review of medicines that are intended to treat a serious condition and that have shown encouraging early clinical results.

  • AstraZeneca Up This Year So Far on Favorable Pipeline Updates
    Zacks19 days ago

    AstraZeneca Up This Year So Far on Favorable Pipeline Updates

    AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

  • AstraZeneca's Lupus Drug Misses Primary Endpoint in Study
    Zacks20 days ago

    AstraZeneca's Lupus Drug Misses Primary Endpoint in Study

    AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.

  • 4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline
    Zacks23 days ago

    4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline

    We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

  • Bloomberg23 days ago

    AstraZeneca's Lupus Treatment Misses Goal in Final-Stage Study

    AstraZeneca Plc’s experimental treatment for lupus failed to meet the goal of a late-stage trial, a blow to the drugmaker’s efforts to develop a therapy for a relatively uncommon disease. Patients with moderate to severe cases of the disease who got the drug, called anifrolumab, didn’t see a statistically significant reduction in disease activity compared with those who received a placebo in the yearlong study, Cambridge, England-based AstraZeneca said Friday in a statement. Astra’s treatment is a monoclonal antibody intended to block the activity of immune-linked inflammation in lupus patients.

  • AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon
    Zacks24 days ago

    AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon

    AstraZeneca (AZN) gains EU approval for a new formulation of its diabetes medicine Bydureon ??? Bydureon BCise.